ImmuCell (ICCC) Competitors $3.58 -0.03 (-0.83%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ICCC vs. ANIX, HOWL, GNLX, COYA, IMUX, ALVR, IVVD, FBLG, RLMD, and ANROShould you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Anixa Biosciences (ANIX), Werewolf Therapeutics (HOWL), Genelux (GNLX), Coya Therapeutics (COYA), Immunic (IMUX), AlloVir (ALVR), Invivyd (IVVD), FibroBiologics (FBLG), Relmada Therapeutics (RLMD), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical products" industry. ImmuCell vs. Anixa Biosciences Werewolf Therapeutics Genelux Coya Therapeutics Immunic AlloVir Invivyd FibroBiologics Relmada Therapeutics Alto Neuroscience Anixa Biosciences (NASDAQ:ANIX) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Does the MarketBeat Community favor ANIX or ICCC? ImmuCell received 99 more outperform votes than Anixa Biosciences when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 68.75% of users gave Anixa Biosciences an outperform vote. CompanyUnderperformOutperformAnixa BiosciencesOutperform Votes2268.75% Underperform Votes1031.25% ImmuCellOutperform Votes12173.33% Underperform Votes4426.67% Which has better earnings and valuation, ANIX or ICCC? ImmuCell has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnixa Biosciences$210K560.85-$9.81M-$0.39-9.38ImmuCell$23.22M1.21-$5.78M-$0.53-6.75 Do analysts recommend ANIX or ICCC? Anixa Biosciences currently has a consensus price target of $7.00, suggesting a potential upside of 91.26%. Given Anixa Biosciences' higher possible upside, research analysts plainly believe Anixa Biosciences is more favorable than ImmuCell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50ImmuCell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the media favor ANIX or ICCC? In the previous week, Anixa Biosciences had 3 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Anixa Biosciences and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.00 beat Anixa Biosciences' score of 0.00 indicating that ImmuCell is being referred to more favorably in the news media. Company Overall Sentiment Anixa Biosciences Neutral ImmuCell Positive Do institutionals and insiders believe in ANIX or ICCC? 29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 22.6% of Anixa Biosciences shares are owned by company insiders. Comparatively, 6.6% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ANIX or ICCC more profitable? Anixa Biosciences has a net margin of 0.00% compared to ImmuCell's net margin of -17.44%. ImmuCell's return on equity of -16.35% beat Anixa Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Anixa BiosciencesN/A -54.79% -50.37% ImmuCell -17.44%-16.35%-9.35% Which has more risk and volatility, ANIX or ICCC? Anixa Biosciences has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. SummaryAnixa Biosciences beats ImmuCell on 10 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get ImmuCell News Delivered to You Automatically Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ICCC vs. The Competition Export to ExcelMetricImmuCellDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.04M$2.31B$5.40B$8.53BDividend YieldN/A0.69%5.13%4.14%P/E Ratio-6.754.22115.5615.18Price / Sales1.2141.611,484.3492.77Price / CashN/A16.3639.6634.07Price / Book1.113.164.665.02Net Income-$5.78M$29.98M$119.06M$225.46M7 Day Performance-1.21%-3.56%0.80%0.37%1 Month Performance-0.83%-0.60%5.65%3.57%1 Year Performance-31.94%-2.99%36.76%29.44% ImmuCell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ICCCImmuCell0.6704 of 5 stars$3.58-0.8%N/A-29.9%$28.04M$23.22M-6.7575Positive NewsANIXAnixa Biosciences2.5672 of 5 stars$3.50-2.5%$7.00+100.0%+14.7%$112.63M$210,000.00-8.975News CoveragePositive NewsGap UpHOWLWerewolf Therapeutics3.8713 of 5 stars$2.56-4.8%$12.00+368.8%+8.8%$111.88M$9.28M-1.8640News CoverageGNLXGenelux2.8516 of 5 stars$3.22-3.3%$18.75+482.3%-79.7%$111.20M$8,000.00-3.3510Analyst ForecastShort Interest ↓News CoverageGap UpCOYACoya Therapeutics2.3406 of 5 stars$7.23+8.6%$16.67+130.5%+51.7%$110.05M$9.55M-9.906Analyst ForecastShort Interest ↑News CoverageHigh Trading VolumeIMUXImmunic2.5679 of 5 stars$1.21-2.4%$11.20+825.6%+14.4%$109.00MN/A-0.8170News CoverageALVRAlloVir2.5674 of 5 stars$0.93+5.0%N/A-38.1%$107.29MN/A-0.76110Upcoming EarningsShort Interest ↓News CoveragePositive NewsIVVDInvivyd2.4769 of 5 stars$0.89-1.9%$11.33+1,169.8%-37.9%$106.60M$2.26M-0.49100Analyst ForecastNews CoverageFBLGFibroBiologics2.7314 of 5 stars$3.02+2.4%$12.00+297.4%N/A$106.18MN/A0.0010Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageRLMDRelmada Therapeutics3.9749 of 5 stars$3.48-0.6%$7.50+115.5%+17.1%$105.01MN/A-1.2110Positive NewsANROAlto Neuroscience2.3264 of 5 stars$3.89-3.5%$24.40+527.2%N/A$104.58M$210,000.000.00N/A Related Companies and Tools Related Companies ANIX Alternatives HOWL Alternatives GNLX Alternatives COYA Alternatives IMUX Alternatives ALVR Alternatives IVVD Alternatives FBLG Alternatives RLMD Alternatives ANRO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ICCC) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ICCC Stock Alerts